Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Holdings Increased by ARK Investment Management LLC

ARK Investment Management LLC increased its stake in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) by 6.9% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,101,038 shares of the biotechnology company’s stock after acquiring an additional 136,074 shares during the period. ARK Investment Management LLC owned approximately 7.80% of Arcturus Therapeutics worth $48,765,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. CANADA LIFE ASSURANCE Co lifted its holdings in shares of Arcturus Therapeutics by 10.5% in the first quarter. CANADA LIFE ASSURANCE Co now owns 4,492 shares of the biotechnology company’s stock valued at $152,000 after buying an additional 428 shares during the period. Price T Rowe Associates Inc. MD grew its stake in shares of Arcturus Therapeutics by 5.7% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 17,004 shares of the biotechnology company’s stock worth $575,000 after purchasing an additional 922 shares during the last quarter. Russell Investments Group Ltd. bought a new stake in shares of Arcturus Therapeutics in the 1st quarter worth approximately $40,000. Public Employees Retirement System of Ohio lifted its stake in Arcturus Therapeutics by 63.8% during the first quarter. Public Employees Retirement System of Ohio now owns 4,620 shares of the biotechnology company’s stock valued at $156,000 after purchasing an additional 1,800 shares during the last quarter. Finally, nVerses Capital LLC acquired a new position in Arcturus Therapeutics in the third quarter worth approximately $42,000. Institutional investors and hedge funds own 94.54% of the company’s stock.

Arcturus Therapeutics Price Performance

ARCT opened at $18.74 on Friday. The stock has a fifty day moving average price of $20.64 and a 200 day moving average price of $24.31. Arcturus Therapeutics Holdings Inc. has a 1 year low of $17.26 and a 1 year high of $45.00.

Arcturus Therapeutics (NASDAQ:ARCT) last released its quarterly earnings data on Monday, August 5th. The biotechnology company reported ($0.64) EPS for the quarter, topping analysts’ consensus estimates of ($1.85) by $1.21. Arcturus Therapeutics had a negative return on equity of 25.47% and a negative net margin of 41.21%. The firm had revenue of $49.86 million for the quarter, compared to the consensus estimate of $21.00 million. During the same quarter in the prior year, the company posted ($1.98) earnings per share. Research analysts expect that Arcturus Therapeutics Holdings Inc. will post -2.6 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on ARCT shares. HC Wainwright restated a “buy” rating and issued a $63.00 target price on shares of Arcturus Therapeutics in a report on Tuesday, October 1st. Cantor Fitzgerald restated an “overweight” rating on shares of Arcturus Therapeutics in a report on Monday, September 9th. Leerink Partners assumed coverage on shares of Arcturus Therapeutics in a research note on Monday, August 12th. They set an “outperform” rating and a $70.00 target price on the stock. Finally, Leerink Partnrs upgraded Arcturus Therapeutics to a “strong-buy” rating in a report on Monday, August 12th. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $71.40.

Insiders Place Their Bets

In other news, COO Pad Chivukula sold 12,000 shares of the stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $20.76, for a total transaction of $249,120.00. Following the transaction, the chief operating officer now owns 435,334 shares of the company’s stock, valued at approximately $9,037,533.84. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 15.30% of the company’s stock.

Arcturus Therapeutics Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.